Background β 2 -Adrenergic receptor agonists accelerate resolution of pulmonary edema in experimental and clinical studies of acute lung injury (ALI).
Methods

Objective:
To determine whether an aerosolized β 2agonist would improve clinical outcomes in patients with ALI. Design: Multi-center, phase III randomized, placebocontrolled clinical trial. Setting: 33 hospitals participating National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Subjects: Patients who were intubated and receiving mechanical ventilation, had bilateral infi ltrates consistent with edema on frontal chest radiograph, had a ratio of PaO 2 to FIO 2 (fraction of inspired oxygen) of 300 or less, and not had clinical evidence of left atrial hypertension. A maximum enrolment of 1,000 patients was planned. Intervention: Patients were randomized to receive aerosolized albuterol (5 mg) or saline placebo every 4 hours for up to 10 days.
Outcomes: Th e primary outcome variable was ventilatorfree days (VFD). Secondary outcome measures included mortality before hospital discharge on day 60 and day 90, the number of intensive care unit (ICU)-free days and the number of organ failure-free days.
Results
Th ere were 282 patients enrolled before the trial was stopped for futility after the second interim analysis. Th e VFDs diff erence with albuterol treatment was unfavourable by -2.2 days, well past the futility boundary of -0.4 VFDs. VFDs were not signifi cantly diff erent between the albuterol and placebo groups (means of 14.4 and 16.6 days, respectively; 95% confi dence interval for the diff erence, -4.7 to 0.3 days; P = 0.087). Rates of death before hospital discharge and the number of organ failure-free days were also not signifi cantly diff erent between the two groups. Th e number of ICU-free days was lower in the albuterol group in comparison with the placebo group (means of 13.5 and 16.2 days respectively; 95% confi dence intervals for the mean diff erence, -4.9 to -0.4 days; P = 0.023). Overall, heart rates were significantly higher in the albuterol group by approximately 5 beats/minute in the fi rst 2 days after randomization (P < 0.05), but rates of new onset atrial fi brillation (10% in both groups) and other cardiac dysrhythmias were not signifi cantly diff erent.
Conclusions
Th ese results suggest that aerosolized albuterol does not improve clinical outcomes in ALI patients. Routine use of β 2 agonist therapy in mechanically ventilated ALI patients cannot be recommended.
Commentary
Acute Lung Injury (ALI) is a major cause of respiratory failure and accounts for signifi cant mortality in critically ill patients [1] . Th e pathophysiology of ALI involves a pro-infl ammatory state with increased permeability and fl uid leakage into the alveoli and interstitium, resulting in pulmonary edema and impaired gas exchange. Th e resolution of alveolar edema is a key factor in recovery from ALI and has therefore been the subject of a substantial number of experimental studies. Many of these studies demonstrate that transportation of sodium and chloride across the alveolar epithelial cells, which can be achieved by increased exogenous cyclic AMP stimulation with β 2 adrenergic agonists, is one of the principal mechanisms in alveolar fl uid clearance [2] . In an ex vivo human lung model, alveolar fl uid clearance doubled with use of a β 2 adrenergic receptor agonist [3] . Furthermore, a single center, phase II randomized trial (BALTI study) showed that patients with ALI receiving an intravenous β 2 adrenergic agonist had lower lung water, lower plateau airway pressures and lower Murray lung injury scores [4] . Th ese laboratory and early clinical data showed promising results to suggest a potential therapeutic role of β 2 adrenergic agonists in improving clinical outcomes when used routinely in patients with ALI.
Based on this preliminary work, the Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network conducted the ALTA study [5] . ALTA was the fi rst multicenter, phase III randomized study to test the role of routine use of a β 2 adrenergic agonist in improving clinical outcomes in patients with ALI. Th e primary outcome measure for this study was the number of ventilator free days (VFDs) by day 28. Th e trial was terminated prematurely after recruitment of only 282 patients of the proposed 1,000 patients at the second interim analysis on grounds of futility. Th e primary outcome, the number of VFDs to day 28, was not signifi cantly diff erent between study groups. Mortality before hospital discharge to days 60 and 90 and the number of organ failure-free days were also not signifi cantly diff erent between the two groups. Th e number of intensive care unit-free days was lower in the albuterol-treated group, suggesting that survivors receiving albuterol spent more time in the ICU than survivors receiving placebo. Also noted was that the albuterol-treated group had a higher heart rate and a tendency towards more fl uid resuscitation. Th e Kaplan-Meier survivor curves suggested worse survival in patients who routinely received albuterol compared to placebo, although the statistical signifi cance of this analysis was not reported.
Th ere are several potential reasons why β 2 adrenergic agonists failed to improve outcomes in this study, despite promising physiological evidence. Among these are the possible lack of signifi cant drug delivery to the aerated, nonedematous lung; the presence of injured alveolar epithelium unable to clear lung water; and down-regulation of β 2 adrenergic receptors with continued use of β 2 adrenergic agonist. Under these scenarios, the β 2 adrenergic agonists would fail to achieve their intended eff ect in real-life clinical settings.
Another possibility is that β 2 adrenergic agonist might successfully improve lung water clearance but harm patients in other ways. For example, β 2 adrenergic agonists cause tachycardia which might lead to greater fl uid resuscitation in the study drug arm. Th is was seen in ALTA, where patients in the β 2 adrenergic agonist arm experi enced higher heart rates and a trend towards higher cumulative fl uid balance in the albuterol-treated arm, particularly on day 2 after randomization. β 2 adrenergic agonists might also lead to lactic acidosis and cardiac arrhythmias, as were noted in another recent randomized controlled trial stopped early for potential harm [6] .
Along these lines, this clinical trial provides an important caveat to our use of surrogate endpoints to guide clinical therapy in the intensive care unit. Surrogate endpoints such as oxygenation and lung water measurements are valid only when they are causally-related to a patient-centered outcome (i.e. mortality), and there is no other link between the therapy of interest and the patient-centered outcomes [7] . Our fi eld has been burned before, with numerous examples of therapies that improved surrogate outcomes but when studied in large trials ultimately were found to harm patients [8] . Of course, physiology is and will always be an important component of clinical decision making in the ICU. However, we must remember that when we make decisions based on physiological rationale alone, we may harm our patients.
With regards to β 2 adrenergic agonists in ALI, there is additional cause for concern. β 2 adrenergic agonists are among the most commonly prescribed medications for mechanically ventilated patients in the ICU. Often they are prescribed routinely, regardless of evidence of signi ficant airfl ow obstruction or intrinsic positive endexpiratory pressure. In these cases, we may truly be causing harm in the absence of benefi t. Th e ALTA study reminds us that no drug in the ICU is completely benign. Although this study certainly does not provide evidence precluding the use of inhaled β 2 adrenergic agonists in the ICU, any routine use in the absence of demonstrated airfl ow obstruction should be reconsidered.
